Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,167 |
Last balance in matching sequence
After 2024-12-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-12-16 · Sale · Disposed 5,000 · Balance 124,714 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2: Partial disposition of RSUs to satisfy tax withholding obligations. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Row 2 · 2024-12-17 · Sale · Disposed 547 · Balance 124,167 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of RSUs to satisfy tax withholding obligations. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Partial disposition of RSUs to satisfy tax withholding obligations.
F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2024 Filed Dec 18, 2024 23:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 547 | $22.04 | $12,055.88 |
DisclosureSEC source: 0001628280-24-051924 · wk-form4_1734563922.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,167 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 23:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,000 | $21.90 | $109,500.00 |
DisclosureSEC source: 0001628280-24-051924 · wk-form4_1734563922.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,714 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,100 | $38.55 | $42,405.00 |
DisclosureSEC source: 0001628280-24-001425 · wk-form4_1705446400.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,711 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $38.15 to $39.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,811 | $37.76 | $68,383.36 |
DisclosureSEC source: 0001628280-24-001425 · wk-form4_1705446400.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,811 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:51 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 14,987 | $25.41 | $380,819.67 |
DisclosureSEC source: 0001628280-23-041962 · wk-form4_1703019085.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,622 F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date. Read SEC document |
| May 05, 2023 Filed May 8, 2023 22:29 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,500 | $40.90 | $265,850.00 |
DisclosureSEC source: 0001628280-23-016560 · wf-form4_168358492995664.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,635 F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $40.59 to $41.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 23:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 875 | $32.62 | $28,542.50 |
DisclosureSEC source: 0001209191-23-014275 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 13,000 F1 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003075 · doc4.xml · derivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:27 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003075 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,135 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002590 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,268 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 01:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 655 | $66.37 | $43,472.35 |
DisclosureSEC source: 0001209191-21-071563 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,868 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 01:44 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071563 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,213 Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 20:53 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,000 | $65.24 | $326,200.00 |
DisclosureSEC source: 0001209191-21-055474 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,868 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.20 to $65.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 20:47 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,500 | $89.21 | $401,445.00 |
DisclosureSEC source: 0001209191-21-043051 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,868 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.90 to $89.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:51 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,125 | $88.73 | $99,821.25 |
DisclosureSEC source: 0001209191-21-013974 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 13,875 F1 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| January 15, 2021 Filed Jan 19, 2021 22:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,000 | $83.28 | $249,840.00 |
DisclosureSEC source: 0001209191-21-004076 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,500 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.98 to $83.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · ownership.nature: Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,000 | $76.08 | $304,320.00 |
DisclosureSEC source: 0001209191-21-001527 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,368 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.86 to $76.26, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001527 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,368 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| December 22, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 9 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,868 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 21, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 8 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,903 Read SEC document |
| December 21, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 7 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,938 Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 500 | $79.59 | $39,795.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,000 F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57 to $79.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| December 17, 2020 Filed Dec 18, 2020 23:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 9,075 | $79.30 | $719,647.50 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,738 F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $79.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 6 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,138 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 35 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,173 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,208 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,408 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,608 Read SEC document |
| December 17, 2020 Filed Dec 29, 2020 22:55 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065396 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,673 Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,500 F3 · ownership.nature: Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust. Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,500 F2 · ownership.nature: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust. Read SEC document |
| December 07, 2020 Filed Dec 18, 2020 23:26 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064497 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,813 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 23:47 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 1,112 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024687 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,813 Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 23:47 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 25,000 | $36.89 | $922,250.00 |
DisclosureSEC source: 0001209191-20-024687 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,925 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.63 to $37.22, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 22:54 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001333 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,925 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · derivative · entry 10 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2023-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options fully vested on the 1 year anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · derivative · entry 9 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 10,000 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options fully vested on the 1 year anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · derivative · entry 8 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 18,000 shares Expires 2023-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options fully vested on the 1 year anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · derivative · entry 7 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 30,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options fully vested on the 1 year anniversary of the grant date. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 65,000 | $19.25 | $1,251,250.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 6 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,130 F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $19.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 7,000 | $4.75 | $33,250.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 5 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 10,000 | $2.62 | $26,200.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 4 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 18,000 | $2.19 | $39,420.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 3 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 30,000 | $5.19 | $155,700.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 2 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 00:32 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,000 | $18.05 | $54,150.00 |
DisclosureSEC source: 0001209191-19-013821 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.92 to $18.18, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 22, 2019 Filed Jan 25, 2019 01:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,000 | $13.58 | $40,740.00 |
DisclosureSEC source: 0001209191-19-005259 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.32 to $14.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:13 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001537 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,130 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 22:20 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,000 | $12.00 | $36,000.00 |
DisclosureSEC source: 0001209191-18-064340 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 02:09 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,000 | $12.74 | $38,220.00 |
DisclosureSEC source: 0001209191-18-059974 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,130 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.58 to $12.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 00:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-056001 · doc4.xml · nonDerivative · entry 1 GIVEN DOUGLAS B · CIK 0001156207 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,130 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.